Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
8-HOUR BAYER vs CHLORZOXAZONE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Irreversibly acetylates cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), inhibiting prostaglandin and thromboxane A2 synthesis, leading to analgesic, antipyretic, anti-inflammatory, and antiplatelet effects.
Chlorzoxazone acts centrally on the spinal cord and subcortical areas of the brain to inhibit multisynaptic reflex arcs involved in producing and maintaining muscle spasm. It may also have some sedative effects.
Relief of pain, fever, and inflammation,Reduction of risk of myocardial infarction in patients with previous MI or unstable angina,Prevention of recurrent ischemic stroke or transient ischemic attack
Adjunct for relief of acute painful musculoskeletal conditions associated with muscle spasm
325-650 mg every 8 hours for pain/fever; 81-325 mg daily for cardiovascular prophylaxis.
250-500 mg orally 3-4 times daily, maximum 750 mg 4 times daily.
15-20 hours (terminal elimination half-life) for salicylate at therapeutic concentrations; prolonged to 20-30 hours at high doses due to saturation of hepatic metabolism (zero-order kinetics).
Terminal elimination half-life approximately 1–2 hours; clinically relevant for muscle relaxant effect duration.
Hepatic hydrolysis by esterases to salicylic acid, which is primarily conjugated in the liver via glucuronidation and glycine conjugation (salicyluric acid), with minor oxidation by cytochrome P450 (CYP2C9) to gentisic acid.
Hepatic, primarily via CYP2E1, also CYP1A2 and CYP3A4
Renal excretion of conjugated salicylate metabolites (75% as salicyluric acid, 10% as salicyl phenolic glucuronide, 5% as salicyl acyl glucuronide, 5% as gentisic acid); 10% free salicylate; approximately 10% eliminated in feces via bile.
Primarily hepatic metabolism followed by renal excretion of metabolites; <1% excreted unchanged in urine; minor biliary/fecal elimination.
80-90% bound to albumin; binding is concentration-dependent and saturable.
Approximately 90–95% bound, primarily to albumin.
0.15-0.2 L/kg for salicylate; distributes into synovial fluid, CNS, and placental tissues; Vd increases in acidosis.
0.46–0.64 L/kg; indicates distribution into total body water.
Oral: Approximately 100% for immediate-release, but extended-release may have slightly reduced absorption (relative bioavailability 85-90% compared to immediate-release).
Oral: nearly complete; rapidly absorbed with extensive first-pass metabolism; systemic bioavailability approximately 30–50% due to first-pass effect.
Avoid in severe renal impairment (Cr Cl <30 m L/min). Use with caution and monitor for bleeding in moderate impairment. Reduce dose or extend interval.
No specific guidelines; use with caution in severe renal impairment (GFR <30 m L/min) due to potential accumulation of active metabolite.
Avoid in severe hepatic impairment. Use with caution in moderate impairment; monitor liver function.
Contraindicated in hepatic impairment; avoid use in Child-Pugh class B or C due to risk of hepatotoxicity.
Not recommended in children <12 years for viral infections due to Reye's syndrome risk (contraindicated).
Not established; safety and efficacy not studied in pediatric patients.
Increased risk of GI bleeding and renal impairment; use lowest effective dose, monitor renal function and signs of bleeding.
Initiate at lower end of dosing range (250 mg 3-4 times daily); monitor for CNS effects (dizziness, drowsiness) and liver function.
None
None
Increased risk of gastrointestinal bleeding and ulceration; Reye syndrome in children with viral illness; Hemorrhagic stroke risk with high doses; Impaired renal function in predisposed patients; Bronchospasm in aspirin-sensitive asthma; Anaphylactic reactions; Use caution in patients with hepatic impairment or G6PD deficiency.
May cause drowsiness, dizziness, or impaired coordination. Caution in patients with hepatic impairment. Discontinue if hypersensitivity reactions occur. Avoid concurrent use with alcohol or other CNS depressants.
Known hypersensitivity to NSAIDs or aspirin; Active peptic ulcer disease or GI bleeding; Severe renal impairment (e GFR <30 m L/min); Hemorrhagic diathesis; Children with viral infection (Reye syndrome); Third trimester of pregnancy; Severe hepatic impairment.
Hypersensitivity to chlorzoxazone or any component of the formulation; impaired hepatic function
Avoid alcohol; may increase risk of gastrointestinal bleeding. No specific food restrictions, but taking with food can reduce gastric irritation. Avoid high-dose vitamin C supplements as they may increase salicylate levels.
No significant food interactions. Take with or without food. Grapefruit juice may increase drug levels; avoid large quantities.
First trimester: No well-controlled studies. Avoid use unless clearly needed. Second and third trimesters: Aspirin should be avoided due to risk of premature closure of ductus arteriosus, oligohydramnios, and increased risk of maternal and fetal bleeding. High doses may cause constriction of ductus arteriosus in utero and persistent pulmonary hypertension in newborn.
Teratogenic risk in humans is not well-studied. No major teratogenic effects have been reported in animal studies. However, as with all medications, use during pregnancy only if clearly needed and after weighing risks vs. benefits. Avoid during first trimester unless necessary.
Small amounts of aspirin are excreted in breast milk. M/P ratio not established. Use with caution in breastfeeding women; avoid high doses due to risk of Reye's syndrome in infants and potential for adverse effects on platelet function.
Not recommended during breastfeeding due to potential for sedation in the infant. No M/P ratio data available.
Pregnancy increases clearance of aspirin; however, dose adjustments are not routinely recommended due to narrow therapeutic index. Use lowest effective dose for shortest duration. Avoid in third trimester.
No dosage adjustment specific to pregnancy is required based on pharmacokinetic data; however, clinical response should be monitored.
8-Hour Bayer is enteric-coated aspirin designed for extended release, reducing gastrointestinal irritation. Onset of action is delayed; not suitable for acute pain or rapid antiplatelet effect. Use with caution in patients with history of peptic ulcer disease or on anticoagulants. Monitor renal function in elderly or dehydrated patients. Avoid in children with viral illness due to Reye's syndrome risk.
Chlorzoxazone is a centrally acting muscle relaxant used for acute musculoskeletal pain. Onset of action is within 1 hour; peak effect at 1-2 hours. Monitor for hepatotoxicity, especially with prolonged use or high doses. Can cause drowsiness and impair motor skills; avoid concurrent use with alcohol or other CNS depressants. Tablets may be crushed for patients with swallowing difficulties.
Take with a full glass of water; do not crush or chew the tablet.,Do not use within 7 days before surgery due to bleeding risk.,If used for pain, consult a doctor if symptoms persist for more than 10 days.,Avoid alcohol while taking this medication to reduce stomach bleeding risk.,Seek medical attention for signs of bleeding (black stools, blood in vomit).
Take exactly as prescribed; do not increase dose or frequency.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Avoid alcohol and other CNS depressants while taking this medication.,Report signs of liver problems: dark urine, yellowing of eyes/skin, persistent nausea, abdominal pain.,Do not suddenly stop taking if used long-term; taper under medical supervision to avoid withdrawal.
No interactions on record
"Lumacaftor is a strong inducer of cytochrome P450 (CYP) 3A4 and other drug-metabolizing enzymes, including CYP2E1. Chlorzoxazone is primarily metabolized by CYP2E1 to its inactive metabolite. Concomitant use increases CYP2E1 activity, leading to accelerated chlorzoxazone clearance and reduced systemic exposure, potentially diminishing its therapeutic effect as a muscle relaxant."
"Chlorzoxazone, a centrally acting muscle relaxant, inhibits the metabolism of diltiazem, a calcium channel blocker, via competitive inhibition of CYP3A4. This leads to increased plasma concentrations of diltiazem, potentially causing enhanced negative chronotropic and vasodilatory effects, resulting in bradycardia, hypotension, or atrioventricular block. Patients may experience dizziness, syncope, or exacerbate heart failure symptoms."
"Butalbital, a barbiturate, induces hepatic cytochrome P450 enzymes (particularly CYP2E1), accelerating the metabolism of chlorzoxazone, a centrally acting muscle relaxant primarily metabolized by CYP2E1. This results in reduced plasma concentrations of chlorzoxazone, leading to diminished therapeutic efficacy and potential loss of symptom control. Clinically, patients may experience inadequate muscle relaxation, requiring dose adjustments or alternative therapy."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about 8-HOUR BAYER vs CHLORZOXAZONE, answered by our medical review team.
8-HOUR BAYER is a NSAID that works by Irreversibly acetylates cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), inhibiting prostaglandin and thromboxane A2 synthesis, leading to analgesic, antipyretic, anti-inflammatory, and antiplatelet effects.. CHLORZOXAZONE is a Skeletal Muscle Relaxant that works by Chlorzoxazone acts centrally on the spinal cord and subcortical areas of the brain to inhibit multisynaptic reflex arcs involved in producing and maintaining muscle spasm. It may also have some sedative effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between 8-HOUR BAYER and CHLORZOXAZONE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of 8-HOUR BAYER is: 325-650 mg every 8 hours for pain/fever; 81-325 mg daily for cardiovascular prophylaxis.. The standard adult dose of CHLORZOXAZONE is: 250-500 mg orally 3-4 times daily, maximum 750 mg 4 times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between 8-HOUR BAYER and CHLORZOXAZONE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. 8-HOUR BAYER is classified as Category C. First trimester: No well-controlled studies. Avoid use unless clearly needed. Second and third trimesters: Aspirin should be avoided due to risk of premature closure of ductus arte. CHLORZOXAZONE is classified as Category C. Teratogenic risk in humans is not well-studied. No major teratogenic effects have been reported in animal studies. However, as with all medications, use during pregnancy only if cl. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.